Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Obesity Surgery
Erschienen in: Obesity Surgery 11/2020

24.07.2020 | Review

Incidental Gastrointestinal Stromal Tumors (GISTs) and Bariatric Surgery: A Review

verfasst von: J. A. Fernández, M. D. Frutos, J. J. Ruiz-Manzanera

Erschienen in: Obesity Surgery | Ausgabe 11/2020

Einloggen, um Zugang zu erhalten

Abstract

The number of bariatric procedures has increased notably, with incidental findings such as gastrointestinal stromal tumors (GISTs) being observed in 2%. The number of studies dealing with incidental findings during bariatric surgery (BS), especially GISTs, is scarce. This review aims to summarize the evidence about GIST diagnosis during BS, and to establish recommendations for the management and follow-up of these patients. A systematic literature search from January 2000 to March 2020 was performed. Retrospective cohort studies, case series, case reports, reviews, and conference abstracts were considered eligible. The present systematic review focused on a descriptive analysis of the data included in the articles selected. The calculated incidence was 0.65%. A change in operative plan was observed in 5% of the cases. In 98% of the cases, GISTs were gastric, with a mean size of 10.3 mm. The mitotic index was < 5 in 99%. Accordingly, all patients were classified as having a very low or low risk of recurrence. R0 resection was achieved in 100% of cases. The incidence of GISTs in patients with MO submitted to BS is considerably higher than in the general population. The diagnosis is related to the depth of preoperative work, the exhaustiveness of the intraoperative examination, and the meticulousness of the histopathological analysis. Although GISTs have a low risk of recurrence and it was previously unnecessary to modify the surgical technique, we recommend that bariatric surgeons are aware of the diagnosis and management of incidental GISTs.
Literatur
1.
2.
Sjöström L, Lindroos AK, Peltonen M, et al. Et al; Swedish obese subjects study scientific group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683–93.CrossRefPubMed
3.
Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724–37. Review. Erratum in: JAMA. 2005 Apr 13;293(14):1728PubMedCrossRef
4.
5.
Lyros O, Moulla Y, Mehdorn M, et al. Coincidental detection of gastrointestinal stromal tumors during laparoscopic bariatric procedures—data and treatment strategy of a German reference center. Obes Surg. 2019;29(6):1858–66.PubMedCrossRef
6.
7.
8.
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.PubMedPubMedCentralCrossRef
9.
Mendes JT, Wilson C, Schammel CMG, et al. GIST identified during bariatric surgery: to treat or not to treat? Surg Obes Relat Dis. 2020;16(2):282–7.PubMedCrossRef
10.
Cazzo E, de Almeida de Saito HP, Pareja JC, et al. Gastric mesenchymal tumors as incidental findings during roux-en-Y gastric bypass. Surg Obes Relat Dis. 2018;14(1):23–8.PubMedCrossRef
11.
Luna C, Luna R, Cabrera LF, et al. Manejo de los tumores del estroma gastrointestinal encontrados en cirugía bariátrica: un desafío quirúrgico. Rev Colom Cir. 2018;33:173–80.CrossRef
12.
Chiappetta S, Stier C, Weiner RA. Invited response letter: "Gastrointestinal stromal tumor after laparoscopic sleeve gastrectomy: be awake before, during, and after a bariatric procedure". Obes Surg. 2018;28(7):2048–9.PubMedCrossRef
13.
Johanet H, Mantilla-Sylvain F, Dabrowski A, et al. Our experience regarding the association between gastrointestinal stromal tumor and bariatric surgery: a response to a letter "Gastrointestinal stromal tumor after laparoscopic sleeve gastrectomy: be awake before, during, and after a bariatric procedure". Obes Surg. 2019;29(2):642–4.PubMedCrossRef
14.
15.
Walędziak M, Różańska-Walędziak A, Kowalewski PK, et al. Bariatric surgery and incidental gastrointestinal stromal tumors—a single-center study: VSJ competition, 1(st) place. Wideochir Inne Tech Maloinwazyjne. 2017;12(3):325–9.PubMedPubMedCentral
16.
Viscido G, Signorini F, Navarro L, et al. Incidental finding of gastrointestinal stromal tumors during laparoscopic sleeve gastrectomy in obese patients. Obes Surg. 2017;27(8):2022–5.PubMedCrossRef
17.
Crouthamel MR, Kaufman JA, Billing JP, et al. Incidental gastric mesenchymal tumors identified during laparoscopic sleeve gastrectomy. Surg Obes Relat Dis. 2015;11(5):1025–8.PubMedCrossRef
18.
Chiappetta S, Theodoridou S, Stier C, et al. Incidental finding of GIST during obesity surgery. Obes Surg. 2015;25(3):579–83.PubMedCrossRef
19.
Yuval JB, Khalaileh A, Abu-Gazala M, et al. The true incidence of gastric GIST—a study based on morbidly obese patients undergoing sleeve gastrectomy. Obes Surg. 2014;24(12):2134–7.PubMedCrossRef
20.
Sanchez BR, Morton JM, Curet MJ, et al. Incidental finding of gastrointestinal stromal tumors (GISTs) during laparoscopic gastric bypass. Obes Surg. 2005;15(10):1384–8.PubMedCrossRef
21.
Joo P, Guilbert L, Sepúlveda EM, et al. Unexpected intraoperative findings, situations, and complications in bariatric surgery. Obes Surg. 2019;29(4):1281–6.PubMedCrossRef
22.
Ge L, Moon RC, Nguyen H, et al. Pathologic findings of the removed stomach during sleeve gastrectomy. Surg Endosc. 2019;33(12):4003–7.PubMedCrossRef
23.
Canil AM, Iossa A, Termine P, et al. Histopathology findings in patients undergoing laparoscopic sleeve gastrectomy. Obes Surg. 2018;28(6):1760–5.PubMedCrossRef
24.
Yardimci E, Bozkurt S, Baskoy L, et al. Rare entities of histopathological findings in 755 sleeve gastrectomy cases: a synopsis of preoperative endoscopy findings and histological evaluation of the specimen. Obes Surg. 2018;28(5):1289–95.PubMedCrossRef
25.
Dogan U, Suren D, Oruc MT, et al. Spectrum of gastric histopathologies in morbidly obese Turkish patients undergoing laparoscopic sleeve gastrectomy. Eur Rev Med Pharmacol Sci. 2017;21(23):5430–6.PubMed
26.
Safaan T, Bashah M, El Ansari W, et al. Histopathological changes in laparoscopic sleeve gastrectomy specimens: prevalence, risk factors, and value of routine histopathologic examination. Obes Surg. 2017;27(7):1741–9. Erratum in: Obes Surg. 2017: Oct;27(10):2778PubMedPubMedCentralCrossRef
27.
Kopach P, Genega EM, Shah SN, et al. The significance of histologic examination of gastrectomy specimens: a clinicopathologic study of 511 cases. Surg Obes Relat Dis. 2017;13(3):463–7.PubMedCrossRef
28.
Lauti M, Gormack SE, Thomas JM, et al. What does the excised stomach from sleeve gastrectomy tell us? Obes Surg. 2016;26(4):839–42.PubMedCrossRef
29.
Miller GC, Reid AS, Brown IS. The pathological findings seen in laparoscopic sleeve gastrectomies for weight loss. Pathology. 2016;48(3):228–32.PubMedCrossRef
30.
Kinsinger LA, Garber JC, Whipple O. A review of sleeve gastrectomy specimen histopathology. Am Surg. 2016;82(11):1101–4.PubMedCrossRef
31.
Ohanessian SE, Rogers AM, Karamchandani DM. Spectrum of gastric histopathologies in severely obese American patients undergoing sleeve gastrectomy. Obes Surg. 2016;26(3):595–602.PubMedCrossRef
32.
Almazeedi S, Al-Sabah S, Al-Mulla A, et al. Gastric histopathologies in patients undergoing laparoscopic sleeve gastrectomies. Obes Surg. 2013;23(3):314–9.PubMedCrossRef
33.
Finnell CW, Madan AK, Ternovits CA, et al. Unexpected pathology during laparoscopic bariatric surgery. Surg Endosc. 2007;21(6):867–9.PubMedCrossRef
34.
Greenbaum D, Friedel D. Unanticipated findings at bariatric surgery. Surg Obes Relat Dis. 2005;1(1):22–4.PubMedCrossRef
35.
36.
Ayoub K, Danial AK, Sankari Tarabishi A, et al. A rare case of incidental finding of GIST during sleeve gastrectomy: case report. Int J Surg Case Rep. 2019;65:161–3.PubMedPubMedCentralCrossRef
37.
Sawalmeh H, Makhdoom M, Khammas A, et al. Incidental finding of gastrointestinal stromal tumors (GISTs) during laparoscopic sleeve gastrectomy. Pulsus J Surg Res. 2019;3(1):87–9.
38.
Bilecik T, Karateke F, Cetinkunar S, et al. Gastrointestinal stromal tumor after laparoscopic sleeve gastrectomy: be awake before, during, and after a bariatric procedure. Obes Surg. 2018;28(6):1785–6.PubMedCrossRef
39.
Gorecki PJ. Laparoscopic sleeve gastrectomy for the management of gastric gastrointestinal stromal tumors: a case report and a new concept. EC Gastroenterol Dig Syst. 2018;5(6):430–6.
40.
Dogan U, Oruc MT, Oner OZ, et al. Treatment of gastric gastrointestinal stromal tumor by laparoscopic sleeve gastrectomy in a morbidly obese patient. J Turgut Ozal Med Cent. 2018;25(1):165–6.
41.
42.
Al-Zetawi M, Shabani H, Al Sawalhi S. Is it feasible to concomitantly resect gastric gastrointestinal stromal tumor during bariatric laparoscopic sleeve gastrectomy? Ann Clin Case Rep. 2017;2:1346.
43.
Al-Amode MA. Incidental gastrointestinal stromal tumor discovered after laparoscopic sleeve gastrectomy. Med J Cairo Univ. 2017;85(3):1169–72.
44.
Atas H, Bulus H, Akkurt G, et al. How to approach incidentally detected gastrointestinal stromal tumor during laparoscopic sleeve gastrectomy: a report of two cases. Euroasian J Hepatogastroenterol. 2016;6(2):173–5.PubMedPubMedCentralCrossRef
45.
Nickel F, Probst P, Fischer L. Would you unblind the patient? A case of incidental T1 N0 R0 GIST in a randomized controlled trial of sleeve gastrectomy versus roux-en-Y gastric bypass for morbid obesity. Surg Obes Relat Dis. 2016;12:e83–5.PubMedCrossRef
46.
de Barros F, Nahoum GP, de Almeida BJ. Treatment of gastrointestinal stromal tumor (GIST) during bariatric surgery. Rev Col Bras Cir. 2015;42(1):67–8.PubMedCrossRef
47.
Roshanravan R, Mina HE, Moslemi S, et al. Gastric gastrointestinal stromal tumor (GIST) incidentally found after laparoscopic sleeve gastrectomy: a case report. Ann Colorectal Res. 2014;2:1–3.CrossRef
48.
Leuratti L, Alfa-Wali M, Bonanomi G. Intraoperative findings during a gastric bypass necessitating the removal of the gastric remnant. To proceed or not with the elective plan? Surg Obes Relat Dis. 2013;9(5):e69–71.PubMedCrossRef
49.
Wang Y, Liu J. Laparoscopic sleeve gastrectomy in the treatment of gastrointestinal stromal tumors in morbid obese patients. BMJ Case Rep 2009;2009.
50.
Beltran MA, Pujado B, Méndez PE, et al. Gastric gastrointestinal stromal tumor (GIST) incidentally found and resected during laparoscopic sleeve gastrectomy. Obes Surg. 2010;20(3):393–6.PubMedCrossRef
51.
de Roover A, Detry O, de Leval L, et al. Report of two cases of gastric cancer after bariatric surgery: lymphoma of the bypassed stomach after roux-en-Y gastric bypass and gastrointestinal stromal tumor (GIST) after vertical banded gastroplasty. Obes Surg. 2006;16(7):928–31.PubMedCrossRef
52.
Abellán I, Ruíz de Angulo D, Parrilla P. Incidental gastric gastrointestinal stromal tumor (GIST) in the excluded stomach after roux-en-Y gastric bypass: a case report and review of the literature. Surg Obes Relat Dis. 2014;10(1):e13–4.PubMedCrossRef
53.
Fernández JA, Frutos MD, Ruiz-Manzanera JJ, et al. Gastrointestinal stromal tumors after laparoscopic gastric bypass for morbid obesity: a diagnostic and therapeutic challenge. Obes Surg. 2019;29(8):2618–21.PubMedCrossRef
54.
Sandvik OM, Søreide K, Kvaløy JT, et al. Epidemiology of gastrointestinal stromal tumors: single-institution experience and clinical presentation over three decades. Cancer Epidemiol. 2011;35(6):515–20.PubMedCrossRef
55.
Ma GL, Murphy JD, Martinez ME, et al. Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study. Cancer Epidemiol Biomark Prev. 2015;24(1):298–302.CrossRef
56.
Søreide K, Sandvik OM, Søreide JA, et al. Global epidemiology of gastrointestinal stromal tumors (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39–46.PubMedCrossRef
57.
Gagner M. Comment on: gastric mesenchymal tumors as incidental findings during roux-en-Y gastric bypass. Surg Obes Relat Dis. 2018;14(1):28–9.PubMedCrossRef
58.
Kawanowa K, Sakuma Y, Sakurai S, et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol. 2006;37(12):1527–35.PubMedCrossRef
59.
Chan CHF, Cools-Lartigue J, Feldman LS, et al. The impact of incidental gastrointestinal stromal tumors on patients undergoing resection of upper gastrointestinal neoplasms. Can J Surg. 2012;55(6):366–70.PubMedPubMedCentralCrossRef
60.
Yuval JB, Elazary R. The true incidence of gastric GIST: an update. Obes Surg. 2018;28(6):1787.PubMedCrossRef
61.
62.
Safaan T, El Ansari W, Bashah M. Compared to what? Is BMI associated with histopathological changes in laparoscopic sleeve gastrectomy specimens? Obes Surg. 2019;29(7):2166–73.CrossRef
63.
Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39:1411–9.PubMedCrossRef
64.
Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70–83.PubMedCrossRef
65.
Coe TM, Fero KE, Fanta PT, et al. Population-based epidemiology and mortality of small malignant gastrointestinal stromal tumors in the USA. J Gastrointest Surg. 2016;20(6):1132–40.PubMedPubMedCentralCrossRef
66.
Stiles ZE, Rist TM, Dickson PV, et al. Impact of body mass index on the short-term outcomes of resected gastrointestinal stromal tumors. J Surg Res. 2017;217:123–30.PubMedCrossRef
67.
SAGES Guidelines Committee. SAGES guidelines for clinical application of laparoscopic bariatric surgery. Surg Endosc. 2008;22(10):2281–300.CrossRef
68.
Schreiner MA. Endoscopy in the obese patient. Gastroenterology Clinics of NA Elsevier Ltd; 2010;39(1):87–97.
69.
Endo Y, Ohta M, Tada K, et al. Clinical significance of upper gastrointestinal endoscopy before laparoscopic bariatric procedures in Japanese patients. Surg Today. 2019;49(1):27–31.PubMedCrossRef
70.
D'Silva M, Bhasker AG, Kantharia NS, et al. High-percentage pathological findings in obese patients suggest that esophago-gastro-duodenoscopy should be made mandatory prior to bariatric surgery. Obes Surg. 2018;28(9):2753–9.PubMedCrossRef
71.
Zeni TM, Frantzides CT, Mahr C, et al. Value of preoperative upper endoscopy in patients undergoing laparoscopic gastric bypass. Obes Surg. 2006;16(2):142–6.PubMedCrossRef
72.
Saarinen T, Kettunen U, Pietiläinen KH, et al. Is preoperative gastroscopy necessary before sleeve gastrectomy and roux-en-Y gastric bypass? Surg Obes Relat Dis. 2018;14(6):757–62.PubMedCrossRef
73.
Wolter S, Duprée A, Miro J, et al. Upper gastrointestinal endoscopy prior to bariatric surgery—mandatory or expendable? An analysis of 801 cases. Obes Surg. 2017;27(8):1938–43.PubMedCrossRef
74.
Hansen SK, Pottorf BJ, Hollis Jr HW, et al. Is it necessary to perform full pathologic review of all gastric remnants following sleeve gastrectomy? Am J Surg. 2017;214(6):1151–5.PubMedCrossRef
75.
AbdullGaffar B, Raman L, Khamas A, et al. Should we abandon routine microscopic examination in bariatric sleeve gastrectomy specimens? Obes Surg. 2016;26(1):105–10.PubMedCrossRef
76.
Walędziak M, Różańska-Walędziak A, Janik MR, et al. Macroscopic evaluation of gastric specimens after laparoscopic sleeve gastrectomy-an optimum screening test for incidental pathologies? Obes Surg. 2019;29(1):28–31.PubMedCrossRef
77.
Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)—update of the NCCN clinical practice guidelines. J Natl Compr Cancer Netw. 2007;5(Suppl 2):S1–29. quiz S30. Review. Erratum in: J Natl Compr Canc Netw. 2007 Aug;5(7):xxx
78.
Casali PG, Abecassis N, Bauer S, et al. Gastrointestinal stromal tumors: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv68–78.PubMedCrossRef
79.
Rebibo L, Hakim S, Dhahri A, et al. Gastric stenosis after laparoscopic sleeve gastrectomy: diagnosis and management. Obes Surg. 2016;26(5):995–1001.PubMedCrossRef
80.
Chang PC, Tai CM, Hsin MC, et al. Surgical standardization to prevent gastric stenosis after laparoscopic sleeve gastrectomy: a case series. Surg Obes Relat Dis. 2017;13(3):385–90.PubMedCrossRef
81.
Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279(5350):577–80.PubMedCrossRef
82.
Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299(5607):708–10.PubMedCrossRef
83.
Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001;20:5054–8.PubMedCrossRef
84.
Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344(14):1052–6.PubMedCrossRef
85.
DeMatteo RP, Ballman KV, Antonescu CR, et al. American College of Surgeons Oncology Group (ACOSOG) intergroup adjuvant GIST study team for the Alliance for Clinical Trials in Oncology. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg. 2013;258(3):422–9.PubMedCrossRef
86.
Dematteo RP, Ballman KV, Antonescu CR, et al. American College of Surgeons Oncology Group (ACOSOG) intergroup adjuvant GIST study team. Adjuvant imatinib mesylate after resection of localized, primary gastrointestinal stromal tumor: a randomized, double-blind, placebo-controlled trial. Lancet. 2009;373(9669):1097–104.PubMedPubMedCentralCrossRef
87.
Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307(12):1265–72.PubMedCrossRef
88.
Yoo C, Ryu MH, Kang BW, et al. Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. J Clin Oncol. 2010;28:1554–9.PubMedCrossRef
89.
Pavlovsky C, Egorin MJ, Shah DD, et al. Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia. Pharmacotherapy. 2009;29(9):1152–6.PubMedCrossRef
90.
Bouchet S, Poulette S, Titier K, et al. Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumors in a real-life setting. Eur J Cancer. 2016;57:31–8.PubMedCrossRef
91.
Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol. 2009;27:3141–7.PubMedCrossRef
92.
Joensuu H, Martín-Broto J, Nishida T, et al. Follow-up strategies for patients with gastrointestinal stromal tumor treated with or without adjuvant imatinib after surgery. Eur J Cancer. 2015;51:1611–7.PubMedCrossRef
93.
Novitsky YW, Kercher KW, Sing RF, et al. Long-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumors. Ann Surg. 2006;243(6):738–45. discussion 745-7PubMedPubMedCentralCrossRef
94.
Wiggins T, Antonowicz SS, Markar SR. Cancer risk following bariatric surgery—systematic review and meta-analysis of national population-based cohort studies. Obes Surg. 2019;29(3):1031–9.PubMedCrossRef
95.
Schauer DP, Feigelson HS, Koebnick C, et al. Association between weight loss and the risk of cancer after bariatric surgery. Obesity (Silver Spring). 2017;25(Suppl 2):S52–7.
96.
Scozzari G, Trapani R, Toppino M, et al. Esophagogastric cancer after bariatric surgery: systematic review of the literature. Surg Obes Relat Dis. 2013;9(1):133–42.PubMedCrossRef
97.
Musella M, Berardi G, Bocchetti A, et al. Esophagogastric neoplasms following bariatric surgery: an updated systematic review. Obes Surg. 2019;29(8):2660–9.PubMedCrossRef
Metadaten
Titel
Incidental Gastrointestinal Stromal Tumors (GISTs) and Bariatric Surgery: A Review
verfasst von
J. A. Fernández
M. D. Frutos
J. J. Ruiz-Manzanera
Publikationsdatum
24.07.2020
Verlag
Springer US
Erschienen in
Obesity Surgery / Ausgabe 11/2020
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-020-04853-1

Weitere Artikel der Ausgabe 11/2020

Obesity Surgery 11/2020 Zur Ausgabe

Letter to the Editor

Recommendations to Manage Patients for Bariatric Surgery in the COVID-19 Pandemic: Experience from China

Original Contributions

Bariatric Surgery and Hospitalization for Heart Failure in Morbidly Obese Patients

Original Contributions

The Impact of the Gastric Twist on Esophagitis Progression After Sleeve Gastrectomy: Mid-Term Endoscopic Findings

Letter to the Editor

Implications of Bariatric Surgery in Patients with Familial Adenomatous Polyposis Requiring Proctocolectomy with Ileal Pouch Anal Anastomosis

Multimedia Article

Surgical Management of Small Intestinal Bacterial Overgrowth After Roux-en-Y Gastric Bypass

Letter to the Editor

Perforated Marginal Ulcer in a COVID-19 Patient. Laparoscopy in these Trying Times?

Neu im Fachgebiet Chirurgie

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Deutlich weniger Infektionen: Wundprotektoren schützen!

08.05.2024 Postoperative Wundinfektion Nachrichten

Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.
Bildnachweise